Armata Pharmaceuticals, Inc.

AMEX:ARMP

Biotechnology

Healthcare
$3.17 -0.28%

-$0.02 today

Market cap
$117.90M
Beta
1.22
P/E (TTM)
-0.9
EPS (TTM)
-$7.74
52W Low $1.81High $16.34

Volume 0.09M

Average 0.07M

ARMP Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Armata Pharmaceuticals, Inc.AMEX: ARMP

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $6.11M rose 12.6% year over year, ahead of the -23.4% change in trailing-twelve-month research & development. Sequentially, it rose 0.7% from the prior quarter. Over 3 fiscal years it compounded at -12.2% a year.

Context

  • Research & development amounted to 483.6% of revenue in FY2025, down 181.7 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +12.6% holds above the trailing-twelve-month pace of -23.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$6.11M+0.7% QoQ
Last fiscal yearDec 2025
$23.72M-31.1% YoY
LTMMar 2026
$24.4M-23.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.6%——
1 year-31.1%——
3-year CAGR-12.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
23.72M USD
Year-over-year change
-31.1%
4-year CAGR
+4.3%

Research & Development vs competitors

How ARMP compares with its peers on the latest reported figures

  • ARMP's LTM Mar 2026 research & development of $24.4M is the lowest of the 2 companies compared; the peer median is $27.77M.
  • Its year-over-year change of -23.4% is the highest of 2, against a peer median of -70.1%.
  • Research & development amounts to 824.8% of revenue for ARMP, versus a peer median of 50.7%.
ARMP Competitors Peer median
Research & Development for ARMP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SPROSpero Therapeutics, Inc.LTM Mar 2026$27.77M -70.1%-6.9%50.7%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$24.4M -23.4%-12.2%824.8%
Peer median (excluding ARMP) $27.77M-70.1%-6.9%50.7%

Competitors are the stored peer set for ARMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.47M5.51M4.53M5.17M4.9M
Cost of Revenue20.02M35.02M972K34.43M1.53M
Gross Profit(15.54M)(29.51M)3.56M(29.25M)3.37M
Gross Margin-347.4%-535.7%78.5%-565.4%68.8%
Research & Development20.02M35.02M33.77M34.43M23.72M
Selling, General & Admin8.28M7.44M10.68M13.18M12.41M
Operating Expenses8.28M7.44M44.45M13.18M34.6M
Depreciation & Amortization1.17M892K972K1.33M1.53M
EBITDA(21.92M)(36M)(65.45M)(6.85M)(155.68M)
EBITDA Margin-490.0%-653.5%-1445.1%-132.4%-3174.5%
Operating Income(23.82M)(36.95M)(40.89M)(42.44M)(31.22M)
Operating Margin-532.5%-670.8%-902.8%-820.2%-636.7%
Interest Income5K29K179K697K388K
Interest Expense64K29K2.63M10.74M16.59M
Other Income / Expenses667K29K(28.16M)23.52M(142.58M)
Income Before Tax(23.16M)(36.92M)(69.05M)(18.92M)(173.8M)
Pre-Tax Margin-517.5%-670.2%-1524.5%-365.6%-3544.0%
Income Tax Expense00000
Net Income(23.16M)(36.92M)(69.05M)(18.92M)(173.8M)
Net Margin-517.5%-670.2%-1524.5%-365.6%-3544.0%
EPS (Basic)(0.96)(1.08)(1.91)(0.52)(4.80)
EPS (Diluted)(0.96)(1.08)(1.91)(0.52)(4.80)
Weighted Avg Shares24.1M34.29M36.08M36.16M36.24M
Weighted Avg Shares (Diluted)24.1M34.29M36.08M36.16M36.24M

Armata Pharmaceuticals, Inc.

AMEX:ARMP

Intrinsic Alpha fair value

Locked

Current Price

$3.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.